Augmentation therapy with alpha-lipoic acid and desvenlafaxine: A future target for treatment of depression?

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 8, 2013, Pages 685-695

  Silva, Márcia Calheiros Chaves ^a   De Sousa, Caren Nádia Soares ^a   Sampaio, Luis Rafael Leite ^a   Ximenes, Naiara Coelho ^a   Araújo, Paulo Victor Pontes ^a   Da Silva, Jéssica Calheiros ^a   De Oliveira, Suzyana Lima ^a   Sousa, Francisca Cléa Florenço ^a   Macêdo, Danielle Silveira ^a   Vasconcelos, Silvânia Maria Mendes ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Alpha lipoic acid; Antidepressants; Behavior; Depression; Desvenlafaxine

Indexed keywords

CORTICOSTERONE; DESVENLAFAXINE; THIOCTIC ACID; ANTIDEPRESSANT AGENT; ANTIOXIDANT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; FORCED SWIMMING TEST; IMMOBILIZATION; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; EXPLORATORY BEHAVIOR; MENTAL STRESS; PSYCHOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; CORTICOSTERONE; CYCLOHEXANOLS; DEPRESSION; DRUG THERAPY, COMBINATION; EXPLORATORY BEHAVIOR; FEMALE; HINDLIMB SUSPENSION; MICE; STRESS, PSYCHOLOGICAL; SWIMMING; THIOCTIC ACID;

EID: 84880284586     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0867-y     Document Type: Article

References (67)

1. Ago Y, Arikawa S, Yata M, Yano K, Abe M, Takuma K, Matsuda T (2008) Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression. Neuropharmacol 55:1355-1363
2. Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T (2013) Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacol 65:29-38
3. Aina Y, Susman JL (2006) Understanding comorbidity with depression and anxiety disorders. J Am Osteopath Assoc 106:S9-S14
4. Alfinito PD, Huselton C, Chen X, Deecher DC (2006) Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res 7:71-78
5. Altemus M (2006) Sex differences in depression and anxiety disorders: potential biological determinants. Horm Behav 50:534-538
6. Archer J (1973) Tests for emotionality in rats and mice: a review. Anim Behav 21:205-235
7. Behr GA, Moreira JCF, Frey BN (2012) Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev 2012:13
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354
9. Berrocoso E, Ikeda K, Sora I, Uhl GR, Sanchez-Blazquez P, Mico JA (2013) Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. Int J Neuropsychopharmacol 16:151-162
10. Bilska A, Wlodek L (2005) Lipoic acid - the drug of the future? Pharmacol Rep 57:570-577
11. Carballedo A, Morris D, Zill P, Fahey C, Reinhold E, Meisenzahl E, Bondy B, Gill M, Moller HJ, Frodl T (2013) Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. Am J Med Genet B Neuropsychiatr Genet 22:32130
12. Carrier N, Kabbaj M (2013) Sex differences in the antidepressant-like effects of ketamine. Neuropharmacol 19:3-8
13. Chung CP, Schmidt D, Stein CM, Morrow JD, Salomon RM (2012) Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatry Res 11:665-668
14. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA (2009) An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 14:183-195
15. Dalby RB, Elfving B, Poulsen PH, Foldager L, Frandsen J, Videbech P, Rosenberg R (2013) Plasma brain-derived neurotrophic factor and prefrontal white matter integrity in late-onset depression and normal aging. Acta Psychiatr Scand 27:12085
16. David DJ, Renard CE, Jolliet P, Hascoet M, Bourin M (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166:373-382
17. David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, Drew M, Craig DA, Guiard BP, Guilloux JP, Artymyshyn RP, Gardier AM, Gerald C, Antonijevic IA, Leonardo ED, Hen R (2009) Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62:479-493
18. De Araujo DP, Lobato Rde F, Cavalcanti JR, Sampaio LR, Araujo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC, Vasconcelos SM (2011) The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review. Int J Neurosci 121:51-57
19. DeMaio W, Kane C, Nichols A, Jordan R (2011) Metabolism studies of desvenlafaxine. J Bioequiv Availab 3:151-160
20. Ferreira PM, Militao GC, Freitas RM (2009) Lipoic acid effects on lipid peroxidation level, superoxide dismutase activity, and monoamines concentration in rat hippocampus. Neurosci Lett 464:131-134
21. Garcia-Garcia AL, Elizalde N, Matrov D, Harro J, Wojcik SM, Venzala E, Ramirez MJ, Del Rio J, Tordera RM (2009) Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry 66:275-282
22. Geerlings MI, Sigurdsson S, Eiriksdottir G, Garcia ME, Harris TB, Sigurdsson T, Gudnason V, Launer LJ (2013) Associations of current and remitted major depressive disorder with brain atrophy: the AGES-Reykjavik Study. Psychol Med 43:317-328
23. Gourley SL, Taylor JR (2009) Recapitulation and reversal of a persistent depression-like syndrome in rodents. Curr Protoc Neurosci Chapter 9:Unit 9.32. doi: 10.1002/0471142301.ns0932s49
24. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64:1465-1475
25. Gregus A, Wintink AJ, Davis AC, Kalynchuk LE (2005) Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav Brain Res 156:105-114
26. Hagen TM, Ingersoll RT, Lykkesfeldt J, Liu J, Wehr CM, Vinarsky V, Bartholomew JC, Ames AB (1999) (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 13:411-418
27. Hill MN, Brotto LA, Lee TT, Gorzalka BB (2003) Corticosterone attenuates the antidepressant-like effects elicited by melatonin in the forced swim test in both male and female rats. Prog Neuropsychopharmacol Biol Psychiatry 27:905-911
28. Huang Z, Zhong XM, Li ZY, Feng CR, Pan AJ, Mao QQ (2011) Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett 493:145-148
29. Iijima M, Ito A, Kurosu S, Chaki S (2010) Pharmacological characterization of repeated corticosterone injection-induced depression model in rats. Brain Res 4:75-80
30. Johnson SA, Fournier NM, Kalynchuk LE (2006) Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor. Behav Brain Res 168:280-288
31. Kalynchuk LE, Gregus A, Boudreau D, Perrot-Sinal TS (2004) Corticosterone increases depression-like behavior, with some effects on predator odor-induced defensive behavior, in male and female rats. Behav Neurosci 118:1365-1377
32. Kleinkauf-Rocha J, Bobermin LD, Machado PD, Goncalves CA, Gottfried C, Quincozes-Santos A (2012) Lipoic acid increases glutamate uptake, glutamine synthetase activity, and glutathione content in C6 astrocyte cell line. Int J Dev Neurosci 31:165-170
33. Kornstein SG, Schneider RK (2001) Clinical features of treatment-resistant depression. J Clin Psychiatry 16:18-25
34. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894-902
35. Kubera M, Curzytek K, Duda W, Leskiewicz M, Basta-Kaim A, Budziszewska B, Roman A, Zajicova A, Holan V, Lason W, Maes M (2013) A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. Brain Behav Immun 9:4
36. Lieberman DZ, Massey SH (2010) Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid 4:67-82
37. Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, Germain JM, Pitrosky B (2008) A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 23:188-197
38. Liebowitz MR, Tourian KA (2010) Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry 12(3):e1-e10
39. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185
40. Liu W, Zhou C (2012) Corticosterone reduces brain mitochondrial function and expression of mitofusin, BDNF in depression-like rodents regardless of exercise preconditioning. Psychoneuroendocrinology 37:1057-1070
41. Macedo DS, Medeiros CD, Cordeiro RC, Sousa FC, Santos JV, Morais TA, Hyphantis TN, McIntyre RS, Quevedo J, Carvalho AF (2012) Effects of alpha-lipoic acid in an animal model of mania induced by d-amphetamine. Bipolar Disord 14:707-718
42. Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352
43. Maes M, Galecki P, Chang YS, Berk M (2011) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35:676-692
44. Mansur RB, Cha DS, Asevedo E, McIntyre RS, Brietzke E (2012) Selfish brain and neuroprogression in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 20:66-71
45. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442
46. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012) Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26:189-204
47. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR D report. Am J Psychiatry 163:1531-1541
48. Murray F, Smith DW, Hutson PH (2008) Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. Eur J Pharmacol 583:115-127
49. Musazzi L, Milanese M, Farisello P, Zappettini S, Tardito D, Barbiero VS, Bonifacino T, Mallei A, Baldelli P, Racagni G, Raiteri M, Benfenati F, Bonanno G, Popoli M (2010) Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 5:8566
50. Nelson JC, Pikalov A, Berman RM (2008) Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat 4:937-948
51. Painsipp E, Kofer MJ, Sinner F, Holzer P (2011) Prolonged depression-like behavior caused by immune challenge: influence of mouse strain and social environment. PLoS One 6:6
52. Papakostas GI, Hallett LA, Smith J, Tossani E, Mascarini A, Burns AM, Birnbaum RJ, Fava M, Alpert JE (2007) A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatr Dis Treat 3:169-172
53. Popoli M, Yan Z, McEwen BS, Sanacora G (2011) The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13:22-37
54. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336
55. Rai D, Zitko P, Jones K, Lynch J, Araya R (2013) Country- and individual-level socioeconomic determinants of depression: multilevel cross-national comparison. Br J Psychiatry 24:24
56. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659-661
57. Salazar MR (2000) Alpha lipoic acid: a novel treatment for depression. Med Hypotheses 55:510-512
58. Sapolsky RM (2001) Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci U S A 98:12320-12322
59. Silva MC, Sampaio LR, Araujo DP, Araujo PV, Monte AS, Rodrigues FT, Woods DJ, Sousa FCF, Fonteles MM, Vasconcelos SM (in press) Central effects of lipoic acid associated with paroxetine in mice. Am J Ther
60. Soczynska JK, Kennedy SH, Chow CS, Woldeyohannes HO, Konarski JZ, McIntyre RS (2008) Acetyl-l-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? Expert Opin Investig Drugs 17:827-843
61. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367-370
62. Szuster-Ciesielska A, Slotwinska M, Stachura A, Marmurowska-Michalowska H, Dubas-Slemp H, Bojarska-Junak A, Kandefer-Szerszen M (2008) Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32:686-694
63. Watson S, Mackin P (2006) HPA axis function in mood disorders. Psychiatry 5:166-170
64. Ye L, Hu Z, Du G, Zhang J, Dong Q, Fu F, Tian J (2012) Antidepressant-like effects of the extract from Cimicifuga foetida L. J Ethnopharmacol 144:683-691
65. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864
66. Zhang Y, Gu F, Chen J, Dong W (2010) Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res 17:141-148
67. Zhao Y, Ma R, Shen J, Su H, Xing D, Du L (2008) A mouse model of depression induced by repeated corticosterone injections. Eur J Pharmacol 581:113-120